Using real-world outcomes data from the STS/ACC TVT Registry, findings from the EVOQUE study presented at TCT 2025 demonstrate favorable safety and effectiveness of transcatheter tricuspid valve replacement (TTVR) at 30 days using the EVOQUE system.

Data were collected from the STS/ACC TVT Registry for patients who underwent commercial TTVR with the EVOQUE system in the U.S. between February 2024 and March 2025. All told, TTVR was attempted in 1,034 patients and the Evoque valve was implanted a total of 1,024. The average patient age was 77 years and 69% were women. Additionally, roughly 84% of patients had atrial fibrillation or atrial flutter, 49% had been hospitalized in the past year, 84% were taking diuretics and 68% were on anticoagulants.

At 30 days, researchers reported low mortality and heart failure hospitalization rates of approximately 3%, respectively. Elimination of tricuspid regurgitation (TR) was also observed, with more than 97% of patients achieving ≤mild TR. Additionally, there were significant improvements in functional capacity and quality of life, and nearly all patients were discharged home following a median hospital stay of two days.

"TTVR using the EVOQUE system has shown superior clinical benefits for patients with symptomatic severe TR compared to those on medical therapy alone," said Rahul Sharma, MBBS, in presenting the findings. "This is the first U.S. real-world TTVR experience."

Clinical Topics: Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Interventions and Imaging, Interventions and Structural Heart Disease, Angiography, Nuclear Imaging

Keywords: Transcatheter Cardiovascular Therapeutics, TCT25, Angiography, Heart Valve Diseases